Skip to main content
Neuland Laboratories Limited. logo

Neuland Laboratories Limited. — Investor Relations & Filings

Ticker · NEULANDLAB ISIN · INE794A01010 LEI · 335800AVHZURTYQ17N08 BSE.NS Manufacturing
Open in API
Filings indexed 947 across all filing types
Latest filing 2021-08-03 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS NEULANDLAB

About Neuland Laboratories Limited.

https://www.neulandlabs.com

Neuland Laboratories Limited specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and provides comprehensive Custom Manufacturing Solutions (CMS). The company focuses on complex chemistry and high-quality standards, operating state-of-the-art manufacturing facilities that comply with international regulatory requirements, including those of the USFDA and EDQM. Its product portfolio spans diverse therapeutic areas such as cardiovascular, central nervous system, anti-infectives, and antiasthmatics. Neuland supports pharmaceutical companies globally through the entire lifecycle of a drug, from early-stage clinical development to commercial-scale production. By leveraging advanced technical expertise and a robust quality management system, the organization delivers reliable chemical synthesis and process optimization services to both innovator and generic drug manufacturers.

Recent filings

Filing Released Lang Actions
Press Release
Interim / Quarterly Report Classification · 100% confidence The document is titled as "Outcome of Board Meeting- Un-audited Standalone & Consolidated Financial Results for the quarter ended June 30, 2021" and references Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, which governs quarterly financial disclosures. It includes detailed unaudited standalone and consolidated financial results for the quarter ended June 30, 2021, with comprehensive financial data such as revenue, expenses, profit before tax, tax expenses, and earnings per share. The document also contains independent auditor's review reports on these unaudited quarterly financial results, prepared under Indian Accounting Standards (Ind AS 34) for interim financial reporting. The presence of detailed financial statements and auditor review confirms this is a quarterly financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2022
2021-08-03 English
Financial Result Updates
Interim / Quarterly Report Classification · 100% confidence The document is a detailed announcement dated August 3, 2021, from Neuland Laboratories Limited regarding the approval and disclosure of unaudited standalone and consolidated financial results for the quarter ended June 30, 2021. It includes the unaudited financial results, notes, and limited review reports by the statutory auditors. The document references Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, which pertains to quarterly financial results disclosures. The presence of detailed financial data, including revenue, expenses, profit before tax, tax expenses, and earnings per share, confirms this is a quarterly financial report. The document is about unaudited quarterly results, not a full annual report or just an announcement of a report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2022
2021-08-03 English
Analysts/Institutional Investor Meet/Con. Call Updates
Capital/Financing Update Classification · 95% confidence The document is a notice addressed to stock exchanges about the upcoming Q1 FY 2021-2022 earnings results announcement and the related earnings call scheduled for August 3, 2021. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015, which governs disclosure of material events. The document does not contain actual financial results or detailed financial statements but rather announces the timing and details of the earnings call and results release. The document length is 2627 characters, which is relatively short and consistent with an announcement rather than a full report or transcript. Therefore, this document is best classified as a Capital/Financing Update (CAP) because it relates to the announcement of earnings results and the earnings call notice, which is a common type of capital market communication. It is not the earnings release itself (ER) nor the call transcript (CT).
2021-07-29 English
Board Meeting — Financial Results/Other business matters
Regulatory Filings Classification · 100% confidence The document text is extremely short (only 54 characters) and contains no substantive content, only a placeholder for an omitted picture. There is no financial data, no report content, no announcements, or any other information to classify as a specific report type. Given the lack of content, the document does not fit any specific filing category and defaults to the fallback category for miscellaneous or non-informative filings, which is Regulatory Filings (RNS).
2021-07-16 English
Updates
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2020-21' and contains detailed sections typical of an annual report, including corporate overview, board of directors, financial highlights, management discussion and analysis, directors' report, corporate governance report, and standalone and consolidated financial statements. It also includes messages from the executive chairman and other senior management, detailed business descriptions, and financial performance data. The document is lengthy (15,000 characters) and contains substantive financial and operational information, not just an announcement or a brief summary. Therefore, it fits the definition of an Annual Report (10-K).
2021-07-08 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2021. It is addressed to stock exchanges and certifies details about securities dematerialized/rematerialized during the period. The document is a compliance certificate related to share transfer and depository regulations, not a financial report or announcement of financial results. It does not contain financial statements or management discussion, nor is it an announcement of voting results or capital changes. It is a regulatory compliance filing. Given the nature and content, this fits best under Regulatory Filings (RNS). The document length is 4433 characters, which is short and consistent with a certificate rather than a full report. Confidence is high due to clear regulatory reference and certificate format.
2021-07-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.